Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by OHSU Knight Cancer Institute
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
OHSU Knight Cancer Institute
ClinicalTrials.gov Identifier:
NCT01620216
First received: June 13, 2012
Last updated: July 28, 2016
Last verified: July 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2017
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)